Ishares Msci Brazil ETF vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Ishares Msci Brazil ETF trades at $43.48 (market cap $11.30B), while Halozyme Therapeutics Inc. Common Stock trades at $112.28 (market cap $12.58B). The key difference: Ishares Msci Brazil ETF and Halozyme Therapeutics Inc. Common Stock are close in size by market cap, and Ishares Msci Brazil ETF is more actively traded (44,036,597 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| EWZ | HALO | |
|---|---|---|
Market Cap | $11.30B | $12.58B |
Volume | 44,036,597 | 2,179,278 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $115.22 |
52-Week Low | $28.79 | $61.63 |
Typical Hold Time | 50 Days | 1 Days |
Enterprise Value | — | $14.49B |
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, is trading at $43.465, up 2.58% with a bullish technical signal from moving averages but bearish oscillators. The ETF shows strong institutional interest with unusual options activity and new positions from firms like Empowered Funds. Recent news highlights Brazil's upcoming election as a key market driver, with investors positioning for potential policy shifts under different candidates.
The outlook for EWZ hinges on Brazil's political landscape and commodity trends. Investment opportunities include geographic diversification and exposure to Brazilian stimulus policies, while risks involve election volatility and US-Brazil trade tensions. Wall Street shows cautious optimism with significant institutional accumulation despite competitive pressure from lower-fee alternatives like FLBR.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →